- RNA-based therapies: A cog in the wheel of lung cancer defense
Parvez Khan et al, 2021, Molecular Cancer CrossRef - Identification of a novel DNA repair inhibitor using an in silico driven approach shows effective combinatorial activity with genotoxic agents against multidrug‐resistant Escherichia coli
Lorenzo Bernacchia et al, 2024, Protein Science CrossRef - Macrophages Are a Double-Edged Sword: Molecular Crosstalk between Tumor-Associated Macrophages and Cancer Stem Cells
Shahang Luo et al, 2022, Biomolecules CrossRef - Pharmacological inhibition of protein tyrosine kinases axl and fyn reduces TNF-α-induced endothelial inflammatory activation in vitro
Sophie F. Ellermann et al, 2022, Frontiers in Pharmacology CrossRef - The Development of AXL Inhibitors in Lung Cancer: Recent Progress and Challenges
Yun Beom Sang et al, 2022, Frontiers in Oncology CrossRef - Phase I Study of Glesatinib (MGCD265) in Combination with Erlotinib or Docetaxel in Patients with Advanced Solid Tumors
Amita Patnaik et al, 2022, Targeted Oncology CrossRef - The Role of the Receptor Tyrosine Kinase Axl in Carcinogenesis and Development of Therapeutic Resistance: An Overview of Molecular Mechanisms and Future Applications
Martha Wium et al, 2021, Cancers CrossRef - Bioluminescent RAPPID Sensors for the Single-Step Detection of Soluble Axl and Multiplex Analysis of Cell Surface Cancer Biomarkers
Eva A. van Aalen et al, 2022, Analytical Chemistry CrossRef - The Dual Role of TAM Receptors in Autoimmune Diseases and Cancer: An Overview
Martha Wium et al, 2018, Cells CrossRef - Galectin-1-mediated MET/AXL signaling enhances sorafenib resistance in hepatocellular carcinoma by escaping ferroptosis
Tung-Wei Hsu et al, 2023, Aging CrossRef - Targeting c-Met and AXL Crosstalk for the Treatment of Hepatocellular Carcinoma
Yeliz Yılmaz et al, 2021, Liver Cancer in the Middle East CrossRef - AXL upregulates c‑Myc expression through AKT and ERK signaling pathways in breast cancers
Xiaobai Sun et al, 2023, Molecular and Clinical Oncology CrossRef